Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

BACKGROUND: SWOG S0421 was a large randomized trial comparing docetaxel/prednisone plus placebo (DPP) to docetaxel/prednisone plus atrasentan over 12 cycles for patients with metastatic castration-resistant prostate cancer (mCRPC). The current report presents the PRO results for this trial, an impor...

詳細記述

保存先:
書誌詳細
出版年:J Patient Rep Outcomes
主要な著者: Unger, Joseph M., Griffin, Katherine, Donaldson, Gary W., Baranowski, Karen M., Good, Margorie J., Reburiano, Eunicia, Hussain, Maha, Monk, Paul J., Van Veldhuizen, Peter J., Carducci, Michael A., Higano, Celestia S., Lara, Primo N., Tangen, Catherine M., Quinn, David I., Wade, James L., III, Vogelzang, Nicholas J., Thompson, Ian M., Jr, Moinpour, Carol M.
フォーマット: Artigo
言語:Inglês
出版事項: Springer International Publishing 2018
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5997724/
https://ncbi.nlm.nih.gov/pubmed/29951640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41687-018-0054-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料